VarCT Diagnostics established

We are very happy to today announce the foundation of VarCT Diagnostics ApS, a sister company to VAR2 Pharmaceuticals. VarCT Diagnostics will, based on our proprietary malaria protein, focus on the development of a universal tool to capture circulating tumour cells (CTC) as means for diagnosis, prognosis and monitoring of cancer during treatment.

The transfer of the research and development activities for CTC capturing to VarCT Diagnostics is an important strategic decision, which will allow us to work dedicatedly in our ambition to bring companion diagnostics linking therapeutic potential with specific patient populations to the market.

Research and development of the therapeutic products remains in VAR2 Pharmaceuticals.